Dinesh M. Kumar - 01 Apr 2026 Form 4 Insider Report for Astrana Health, Inc. (ASTH)

Reporting relationship: Chief Medical Officer
Issuer ticker: ASTH
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2026, 17:36:47 UTC
Prior SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathy Diep, as Attorney-in-Fact

Key filing fact

Dinesh M. Kumar filed Form 4 for Astrana Health, Inc. (ASTH) on 03 Apr 2026.

Key facts

This page summarizes Dinesh M. Kumar's Form 4 filing for Astrana Health, Inc. (ASTH).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Apr 2026, 17:36.

Change

Previous filing in this sequence was filed on 09 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001850439 Primary reporting owner

Kumar Dinesh M.

Relationship: Chief Medical Officer
Address: C/O ASTRANA HEALTH, INC., 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA
Signature: /s/ Kathy Diep, as Attorney-in-Fact
Signature date: 03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASTH transaction

Common Stock

Award

Transaction value
Shares: +35,300
Change %: +18%
Price: $0.000000^*
Shares after: 235,635
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

ASTH transaction

Common Stock

Tax liability

Transaction value
Shares: -57,980
Change %: -25%
Price: $24.51^*
Shares after: 177,655
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Shares delivered to the reporting person pursuant to the vesting of performance-based restricted stock units that vested upon achievement of performance goals for the applicable performance period. The reporting person reported an acquisition of 67,238 performance-based restricted stock units on a Form 4 filed November 12, 2024, which represented the number of shares that would be delivered if target performance was achieved during the performance period. Actual performance exceeded the target performance for the performance period, which resulted in an additional grant of 35,300 shares.

Footnote F2

Represents the surrender of shares to offset against tax withholding obligations associated with certain restricted stock and restricted stock units that vested on April 1, 2026.

Footnote F3

Includes 28,378 shares of restricted stock, which will vest on January 23, 2027 (subject to continuous employment with the Issuer). Also includes 20,027 restricted stock units, which will vest in six equal semi-annual installments beginning on September 5, 2026 (subject to continuous employment with the Issuer).

Footnote F4

Includes 1,405 shares acquired under the Issuer's Employee Stock Purchase Plan.